Sath Shukla Sells 155,333 Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO) CEO Sath Shukla sold 155,333 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $0.78, for a total value of $121,159.74. Following the sale, the chief executive officer now owns 1,736,883 shares of the company’s stock, valued at $1,354,768.74. The trade was a 8.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Spero Therapeutics Trading Down 1.6 %

Shares of SPRO stock opened at $0.86 on Friday. Spero Therapeutics, Inc. has a twelve month low of $0.74 and a twelve month high of $1.89. The company’s 50-day moving average price is $0.99 and its 200-day moving average price is $1.19. The stock has a market cap of $47.07 million, a price-to-earnings ratio of 12.33 and a beta of 0.61.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on SPRO shares. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Spero Therapeutics in a research report on Thursday, January 30th. Evercore ISI downgraded shares of Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price objective for the company. in a report on Friday, December 20th. Cantor Fitzgerald restated an “overweight” rating on shares of Spero Therapeutics in a report on Friday, November 15th. Finally, TD Cowen restated a “hold” rating on shares of Spero Therapeutics in a research report on Monday, November 18th.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.